Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase II Study of AST-001 Injection in Recurrent/Progressive High-grade Glioma
CTR20263081Phase 2Active
- Sponsor
- Accendatech
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Threonine in high-grade glioma (HGG), sponsored by Accendatech. Started Aug 2026; status: active.
02
Drugs
Threonine
03
Conditions
high-grade glioma (HGG)
Beyond the preview
Go deeper on CTR20263081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263081.